Aemetis (NASDAQ:AMTX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Aemetis (NASDAQ:AMTX) in a research report report published on Friday,Benzinga reports. The firm currently has a $28.00 price objective on the specialty chemicals company’s stock.

Other equities research analysts also recently issued research reports about the company. Truist Financial reaffirmed a “hold” rating and set a $3.50 price target (down previously from $4.00) on shares of Aemetis in a report on Wednesday, July 31st. Ascendiant Capital Markets reduced their target price on shares of Aemetis from $20.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. StockNews.com raised shares of Aemetis to a “sell” rating in a report on Wednesday, July 31st. Finally, UBS Group reduced their price objective on Aemetis from $8.25 to $7.75 and set a “buy” rating for the company in a report on Monday, August 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.95.

Aemetis Stock Performance

AMTX traded down $0.24 on Friday, hitting $3.83. 713,435 shares of the company were exchanged, compared to its average volume of 806,729. The stock’s fifty day moving average is $2.80 and its 200-day moving average is $3.06. The company has a market cap of $190.50 million, a PE ratio of -1.69 and a beta of 1.23. Aemetis has a 12 month low of $2.10 and a 12 month high of $7.03.

Aemetis (NASDAQ:AMTX) last released its quarterly earnings data on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.09. The firm had revenue of $81.44 million for the quarter, compared to analyst estimates of $77.79 million. During the same quarter in the prior year, the firm earned ($0.59) earnings per share. As a group, equities research analysts expect that Aemetis will post -2.1 EPS for the current fiscal year.

Institutional Trading of Aemetis

A number of institutional investors have recently bought and sold shares of AMTX. FMR LLC raised its position in shares of Aemetis by 68.2% in the third quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company’s stock valued at $52,000 after buying an additional 9,137 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Aemetis during the 1st quarter valued at $60,000. Hutchinson Capital Management CA acquired a new stake in shares of Aemetis during the 2nd quarter worth $70,000. State Board of Administration of Florida Retirement System bought a new position in shares of Aemetis in the first quarter worth $84,000. Finally, Barclays PLC increased its position in shares of Aemetis by 274.6% in the third quarter. Barclays PLC now owns 47,496 shares of the specialty chemicals company’s stock worth $109,000 after purchasing an additional 34,816 shares during the period. Institutional investors own 27.02% of the company’s stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.